What we are learning about CLL treatments and the microenvironment
Frontline therapy and the role of high-dose consolidation in mantle cell lymphoma
Mechanism of action of venetoclax (ABT-199) and its side effects
HDACs in multiple myeloma: potential benefits in maintenance phase
Is venetoclax appropriate for relapsed CLL patients?